US EditionPublished • loading... • Updated
Johnson & Johnson reports Q4 and Full-Year 2025 results
- On Wednesday, Jan. 21, Johnson & Johnson reported adjusted quarterly earnings of US$6-billion, or US$2.46 per share, and revenue of US$24.56-billion, topping forecasts.
- Innovative Medicine performance drove a 10 per cent sales rise to US$15.76-billion, while medical devices sales reached US$8.8-billion despite Stelara sales declines and tariff pressures.
- The payout represents a quarterly dividend of $1.30 per share payable on Tuesday, March 10th, with institutional owners holding 69.55% of the stock.
- Traders pushed shares lower in premarket trading, while analyst firms including Wells Fargo, Goldman Sachs, and Morgan Stanley raised targets and ratings recently.
- The company signaled it raised 2026 outlook despite a `hundreds of millions of dollars` hit from a drug‑pricing deal, with Jan. 14 Tecvayli MajesTEC-9 topline results supporting growth.
Insights by Ground AI
21 Articles
21 Articles
Johnson & Johnson Crushes Patent, Pricing Probs
Johnson & Johnson is vying to become the first among its healthcare peers to make $100 billion in annual revenue. The pharma company said yesterday it broke past $94 billion in 2025 and expects to reach 12 figures this year. Both measures, along with last quarter’s revenue of nearly $25 billion, exceeded analysts’ estimates. Expectations for next year were especially rosy considering Johnson & Johnson agreed to slash drug prices this month as pa…
American pharmaceuticals reached US$ 24.5 billion between October and December, growth of 9.1% over the same period of 2024
·Brazil
Read Full Article
Coverage Details
Total News Sources21
Leaning Left1Leaning Right1Center8Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
Factuality
To view factuality data please Upgrade to Premium
